Danhong injection in cardiovascular and cerebrovascular diseases: Pharmacological actions, molecular mechanisms, and therapeutic potential.

Atherosclerosis Cardiac hypertrophy Cardiovascular diseases Coronary artery disease Danhong injection Danshensu (PubChem CID: 11600642) Ferulic acid (PubChem CID: 445858) Hydroxysafflor yellow A (PubChem CID: 6443665) Protocatechuic aldehyde (PubChem CID: 8768) Rosmarinic acid (PubChem CID: 5281792) Salvianolic acid A (PubChem CID: 5281793) Salvianolic acid B (PubChem CID: 11629084) Salvianolic acid D (PubChem CID: 75412558) Stroke

Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
01 2019
Historique:
received: 01 08 2018
revised: 01 11 2018
accepted: 04 11 2018
pubmed: 9 11 2018
medline: 14 5 2019
entrez: 9 11 2018
Statut: ppublish

Résumé

Cardiovascular and cerebrovascular diseases are the main cause of mortality worldwide, currently with less than optimum therapeutic options. Danhong injection (DHI) is a medicinal preparation based on two eminent Chinese herbal medicines, Salviae Miltiorrhizae (Dan Shen; family: Lamiaceae) and Flos Carthami (Hong Hua; family: Compositae/Asteraceae). DHI has been mainly used in the clinical therapy of cardiovascular (such as acute coronary syndrome and angina pectoris) and cerebrovascular diseases (such as stroke) in China for many years. The pharmacological properties of DHI include anti-inflammatory, anti-oxidant, anti-coagulatory, hypolipidemic, anti-apoptotic, vasodilatory, and angiogenesis-promoting actions. DHI offers a safe and effective therapeutic agent against cardiovascular and cerebrovascular diseases by modulating multiple disease-relevant signaling pathways and molecular targets. Herein, we provide a comprehensive review of the phytochemistry, therapeutic effects, molecular mechanisms, and adverse reactions of DHI in cardiovascular and cerebrovascular diseases. We also highlight the latest pharmacological advances and therapeutic potential of this promising herb-derived cardiovascular drug preparation.

Identifiants

pubmed: 30408571
pii: S1043-6618(18)30856-9
doi: 10.1016/j.phrs.2018.11.006
pii:
doi:

Substances chimiques

Drugs, Chinese Herbal 0
danhong 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

62-75

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Xiaojun Feng (X)

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

Yi Li (Y)

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

Yanan Wang (Y)

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

Lingli Li (L)

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.

Peter J Little (PJ)

School of Pharmacy, The University of Queensland, Wooloongabba, QLD 4102, Australia; Department of Pharmacy, Xinhua College of Sun Yat-sen University, Guangzhou 510520, China.

Suo-Wen Xu (SW)

Aab Cardiovascular Research Institute, University of Rochester, NY, 14623, USA. Electronic address: suowen.xu@gmail.com.

Sheng Liu (S)

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China. Electronic address: lslcclhl@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH